BACKGROUND: Despite increased risk of venous thromboembolism (VTE) among hospitalized patients with inflammatory bowel disease (IBD), pharmacologic prophylaxis rates remain low. We sought to understand the reasons for this by assessing factors associated with VTE prophylaxis in patients with IBD and the safety of its use. METHODS: This was a retrospective cohort study conducted among patients hospitalized between January 2013 and August 2018. The primary outcome was VTE prophylaxis, and exposures of interest included acute and chronic bleeding. Medical records were parsed electronically for covariables, and logistic regression was used to assess factors associated with VTE prophylaxis. RESULTS: There were 22,499 patients studied, including 474 (2%) with IBD. Patients with IBD were less likely to be placed on VTE prophylaxis (79% with IBD, 87% without IBD), particularly if hematochezia was present (57% with hematochezia, 86% without hematochezia). Among patients with IBD, admission to a medical service and hematochezia (adjusted odds ratio 0.27; 95% CI, 0.16-0.46) were among the strongest independent predictors of decreased VTE prophylaxis use. Neither hematochezia nor VTE prophylaxis was associated with increased blood transfusion rates or with a clinically significant decline in hemoglobin level during hospitalization. CONCLUSION: Hospitalized patients are less likely to be placed on VTE prophylaxis if they have IBD, and hematochezia may drive this. Hematochezia appeared to be minor and was unaffected by VTE prophylaxis. Education related to the safety of VTE prophylaxis in the setting of minor hematochezia may be a high-yield way to increase VTE prophylaxis rates in patients with IBD.
BACKGROUND: Despite increased risk of venous thromboembolism (VTE) among hospitalized patients with inflammatory bowel disease (IBD), pharmacologic prophylaxis rates remain low. We sought to understand the reasons for this by assessing factors associated with VTE prophylaxis in patients with IBD and the safety of its use. METHODS: This was a retrospective cohort study conducted among patients hospitalized between January 2013 and August 2018. The primary outcome was VTE prophylaxis, and exposures of interest included acute and chronic bleeding. Medical records were parsed electronically for covariables, and logistic regression was used to assess factors associated with VTE prophylaxis. RESULTS: There were 22,499 patients studied, including 474 (2%) with IBD. Patients with IBD were less likely to be placed on VTE prophylaxis (79% with IBD, 87% without IBD), particularly if hematochezia was present (57% with hematochezia, 86% without hematochezia). Among patients with IBD, admission to a medical service and hematochezia (adjusted odds ratio 0.27; 95% CI, 0.16-0.46) were among the strongest independent predictors of decreased VTE prophylaxis use. Neither hematochezia nor VTE prophylaxis was associated with increased blood transfusion rates or with a clinically significant decline in hemoglobin level during hospitalization. CONCLUSION: Hospitalized patients are less likely to be placed on VTE prophylaxis if they have IBD, and hematochezia may drive this. Hematochezia appeared to be minor and was unaffected by VTE prophylaxis. Education related to the safety of VTE prophylaxis in the setting of minor hematochezia may be a high-yield way to increase VTE prophylaxis rates in patients with IBD.
Authors: Geoffrey C Nguyen; Sanjay K Murthy; Brian Bressler; Mindy C W Lam; Ali Alali; Asmae Toumi; Jason Reinglas; Adam Rampersad; Adam V Weizman; Waqqas Afif Journal: Inflamm Bowel Dis Date: 2017-05 Impact factor: 5.325
Authors: Alain Bitton; Donald Buie; Robert Enns; Brian G Feagan; Jennifer L Jones; John K Marshall; Scott Whittaker; Anne M Griffiths; Remo Panaccione Journal: Am J Gastroenterol Date: 2011-11-22 Impact factor: 10.864
Authors: Adam S Faye; Timothy Wen; Ashwin N Ananthakrishnan; Simon Lichtiger; Gilaad G Kaplan; Alexander M Friedman; Garrett Lawlor; Jason D Wright; Frank J Attenello; William J Mack; Benjamin Lebwohl Journal: Clin Gastroenterol Hepatol Date: 2019-07-20 Impact factor: 11.382
Authors: Timothy Wen; Jason D Wright; Dena Goffman; Mary E D'Alton; William J Mack; Frank J Attenello; Alexander M Friedman Journal: Am J Obstet Gynecol Date: 2018-07-11 Impact factor: 8.661
Authors: Adriana R Andrade; Luísa L Barros; Matheus F C Azevedo; Alexandre S Carlos; Aderson O M C Damião; Aytan M Sipahi; André Z A Leite Journal: Clin Transl Gastroenterol Date: 2018-04-03 Impact factor: 4.488
Authors: Pablo A Olivera; Stephane Zuily; Paulo G Kotze; Veronique Regnault; Sameer Al Awadhi; Peter Bossuyt; Richard B Gearry; Subrata Ghosh; Taku Kobayashi; Patrick Lacolley; Edouard Louis; Fernando Magro; Siew C Ng; Alfredo Papa; Tim Raine; Fabio V Teixeira; David T Rubin; Silvio Danese; Laurent Peyrin-Biroulet Journal: Nat Rev Gastroenterol Hepatol Date: 2021-08-27 Impact factor: 46.802
Authors: Martine A Aardoom; Renz C W Klomberg; Polychronis Kemos; Frank M Ruemmele; C H Heleen van Ommen; Lissy de Ridder; Nicholas M Croft Journal: J Crohns Colitis Date: 2022-06-24 Impact factor: 10.020